BioSpace News Archive

Lone Star Bio

Lantern Pharma Announces Abstract on Effectiveness of LP-284 in Hematologic Cancers Accepted for Presentation at the 63rd American Society of Hematology (ASH) Annual Meeting

Lantern Pharma (NASDAQ: LTRN), today announced that Lantern Pharma’s abstract on the effectiveness of LP-284 in hematologic cancers has been accepted as a poster at the upcoming 63rd American Society of Hematology (ASH) Annual Meeting.

November 4, 2021
·
5 min read
Medtronic study shows patients with high blood pressure are interested in an interventional procedure treatment option

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced findings from a new study of the Patient Preferences for the Treatment of Hypertension.

November 4, 2021
·
7 min read
Pharm Country

Regeneron Presentations at ASH Highlight Expanding Clinical Research in Blood Cancers and Disorders

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new and updated data from its diverse hematology program in blood cancers and disorders will be presented at the 2021 American Society of Hematology (ASH) Annual Meeting from December 11-14 in Atlanta, GA.

November 4, 2021
·
11 min read
Business

Greenlight Biosciences (ENVI) Adds Two World-Renowned Scientists To Its Scientific Advisory Board

GreenLight Biosciences is delighted to announce the appointment of Professor Diane E. Griffin, MD, PhD, and Emmanuel Hanon, DVM, PhD, to its Human Health Scientific Advisory Board.

November 4, 2021
·
3 min read
Lone Star Bio

Cellenkos® Inc. Secures $15 Million Series A Financing to Accelerate the Development of Transformation Cell-Based Therapies

Cellenkos® Inc. (“Cellenkos”), a biotech company focused on developing transformative novel T regulatory (Treg) cell therapies to treat autoimmune and inflammatory disorders, today announced the close of $15 million Series A financing led by BVCF Management Ltd (“BVCF”).

November 4, 2021
·
3 min read
Pharm Country

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition.

November 4, 2021
·
44 min read
Drug Development

Karyopharm Announces New Interim Phase 2 Selinexor Data in Myelofibrosis Selected for Oral Presentation at the American Society of Hematology 2021 Annual Meeting and Exposition

Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that an abstract detailing new data from a Phase 2 study evaluating selinexor.

November 4, 2021
·
20 min read
Genetown

Ultivue to Participate in the Stifel 2021 Virtual Healthcare Conference

Ultivue, an industry leader in multiplexing tools for tissue biomarker analysis, will participate in the Stifel 2021 Virtual Healthcare Conference to be held November 15th – 17, 2021

November 4, 2021
·
1 min read
Biotech Bay

Biomea Fusion Publishes Abstract on BMF-219 at ASH Annual Meeting

Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), today announced that an abstract containing preclinical data for BMF-219 has been published in Blood, the journal of the American Society of Hematology.

November 4, 2021
·
8 min read
Sobi to present new data at the ASH 2021 Annual Meeting

Sobi™ will present new data at the 63rd Annual Meeting of the American Society of Hematology (ASH) taking place from 11-14 December 2021 .

November 4, 2021
·
12 min read